Patents by Inventor Seonhun Kwon

Seonhun Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
    Patent number: 9814782
    Abstract: The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 14, 2017
    Assignee: ALTEOGEN INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Seonhun Kwon, Sunbae Lee, Sun-ah Yoo, Yong Mo Kim
  • MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME
    Publication number: 20170119903
    Abstract: The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.
    Type: Application
    Filed: December 29, 2016
    Publication date: May 4, 2017
    Applicant: Alteogen Inc.
    Inventors: Soon Jae Park, Hye-Shin Chung, Seonhun Kwon, Sunbae Lee, Sun-Ah You, Yong Mo Kim
  • MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME
    Publication number: 20160102148
    Abstract: The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.
    Type: Application
    Filed: February 22, 2013
    Publication date: April 14, 2016
    Applicant: ALTEOGEN INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Seonhun Kwon, Sunbae Lee, Sun-ah Yoo, Yong Mo Kim